*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Antileukotriene Drugs in The Treatment of Atopic Dermatitis in Children

Author: MIRRAKHIMOVA MAKTUBA XABIBULLAYEVNA, ABDULLAEVA DILOROM TELMANOVNA, ABDULLAEVA DILAFRUZ GAYRATOVNA, SAGDULLAYEVA MAFURA ABDUKARIMOVNA, ABDULLAYEVA MUXLISA MASRUROVNA
Abstract: The object of the study. To evaluate clinical efficacy and tolerability of Montelucast drugs in the treatment of atopic dermatitis in children. Materials and methods. The studies were carried out in patients who were inpatient treatment at the Department of Allergology on the basis of the Department of Pediatric Diseases No. 1 of the Tashkent Medical Academy. 20 children aged 2 up to 12 years with a diagnosis of atopic dermatitis participated in the research. Results and discussion. The drug tolerance was assessed on the basis of subjective symptoms and sensations, which the patient or his parents reported independently and taking into account objective data obtained by the doctor. The changes of laboratory parameters by time, as well as the frequency of occurrence and nature of adverse reactions were taken into account. The assessment of the tolerability of the drug under the study was carried out on the basis of the above criteria in points on a scale from 0 to 4 points. After the use of montelukast drugs, both domestically produced and Singlon, the clinical manifestations of allergy decreased. Only such a symptom of the disease as cough was observed in 20-30% of children, in the form of coughing. All patients had a significant decrease in the content of eosinophils in the peripheral blood at the 4th week of therapy. The study of the IgE content in the blood of patients, as the main indicator of the allergological profile, also revealed a significant improvement in the results of the treatment with the tested drugs (p <0.001). All children showed a decrease in the level of total IgE in the blood one month after taking the drugs. The greatest decrease was noted in children who received Singlon (p <0.001). Studies have shown that taking montelukast drugs leads to a decrease in the level of cys-LT in the urine. At the same time, in children who received Singlon, a more significant decrease in the level of cys-LT was noted than in children who received the domestic drug Montulak (p <0.05). Conclusion. Studies have confirmed that montelukast can be effective as a mono-drug for severe atopic dermatitis, especially in cases of combination with asthma and allergic rhinitis.
Keyword: Atopic dermatitis, children, montelukast, efficacy, tolerance, Montulak
DOI: https://doi.org/10.31838/ijpr/2021.13.01.326
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free